Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$68.28 USD

68.28
11,965,096

-1.40 (-2.01%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Neena Mishra headshot

Should You Buy Oil & Gas ETFs Now?

Energy ETFs rebounded strongly in November but are still down significantly for the year

Productivity Increases in Q3

Productivity Increases in Q3

Moderna (MRNA) to Supply More Doses of COVID-19 Vaccine to Canada

Moderna (MRNA) announces deal to supply 20 million additional doses of its COVID-19 vaccine candidate, mRNA-1273, to the Canadian Government, upon potential approval. The total tally is now 40 million doses.

Mark Vickery headshot

Markets Find Vaccine-Rally Equilibrium; AZO Mixed in Q1

Great Britain injects its first Pfizer (PFE)-BioNTech (BNTX) vaccine patients today, marking a momentous occasion whereby the world may soon return to pre-pandemic activities.

Sweta Killa headshot

Small-Cap ETFs Face Off: IWM Vs. IJR

Small-cap companies are closely tied to the U.S. economy and are thus poised to outperform when the economy improves.

Pfizer (PFE) Up 14% in 3 Months on COVID-19 Vaccine Progress

Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is now approved for emergency use in United Kingdom and Bahrain.

Mark Vickery headshot

Markets Close Mixed; Toll Brothers (TOL) Puts Up Record Quarter

It's the hottest home market Toll Brothers has seen in 30 years, with net signed contracts +68% -- an all-time high for any quarter in the company's history.

Sejuti Banerjea headshot

Can Restaurant Stocks Move Higher?

Restaurant companies have been done a lot of innovating this year and they should do much better next year as pandemic concerns wane.

The Zacks Analyst Blog Highlights: Cisco Systems, CVS Health, Moderna, Pfizer and Hilton Worldwide

The Zacks Analyst Blog Highlights: Cisco Systems, CVS Health, Moderna, Pfizer and Hilton Worldwide

Markets Hit Record Highs, Promise Further Growth: 5 Top Picks

Promising vaccine news and hopes of further fiscal stimulus helped benchmark indexes to close at record highs, making this a prudent time to invest in names like Cabot (CBT) and Forestar (FOR)

Sweta Killa headshot

Holiday Shopping Shifts to E-Commerce: ETFs to Tap

Given the digital shopping boom, stocks in the Internet and e-commerce retail space look poised for solid gains this holiday season.

Urmimala Biswas headshot

3 Growth Stocks to Tap the COVID-Driven Shift in MedTech

To beat the pandemic blues and maximize capital gains, investors can now scoop up these fundamentally-strong MedTech growth stocks.

Sheraz Mian headshot

Top Analyst Reports for Cisco, CVS Health & Moderna

Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems, Inc. (CSCO), CVS Health Corporation (CVS) and Moderna, Inc. (MRNA).

John Blank headshot

The Vaccines Are Here. Are We Out of the Woods Now?

It almost seems like we are just an appointment at the doctor's office away from opening up our economy again.

Sweta Killa headshot

Stocks to Track in December as Markets Peak

December is likely to be filled with events or stock/sector specific news that could provide a boost to the stocks.

Biotech Stock Roundup: BIIB & SAGE Alliance, MRNA, BNTX Coronavirus Updates & More

Collaborations, and pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and BioNTech (BNTX) provide key updates.

Sweta Killa headshot

After a Historic November, What Awaits ETFs in December?

Let's delve into some of the major events of December and learn how to tap the opportune moments with ETFs.

Pfizer/BioNTech's COVID-19 Vaccine Gets Approval in U.K.

Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate becomes the first-ever vaccine to get authorization.

Encouraging News on COVID-19 Vaccine

Encouraging News on COVID-19 Vaccine

Mark Vickery headshot

ADP Reports 307K New Jobs, Revisions Up

307K new private-sector jobs was lower than expected, and beneath the upwardly revised 404K from October.

Sweta Killa headshot

5 International ETFs That Outstripped US Market in November

November was a banner month for the global stock market despite the rising number of COVID-19 cases.

Cimarex Energy (XEC) Up 48.6% QTD: What's Behind the Rally?

Improving oil prices on positive coronavirus vaccine results aid Cimarex (XEC).

Stock Market News for Dec 2, 2020

U.S. stock markets closed higher on Tuesday on the back of optimism surrounding COVID-19 vaccine.

Pfizer/BioNTech Seek Marketing Nod for COVID-19 Vaccine in EU

Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is 95% effective in final analysis.

Kinjel Shah headshot

Will Americans Get COVID-19 Vaccine Sooner Than Europeans?

Moderna (MRNA), and Pfizer (PFE)/BioNTech (BNTX) file for emergency use authorization of their COVID-19 vaccine candidates in Europe